Project I.g.i 1 Game Free Download

[Laszlo Perry]

Currentlythe tools we have to address problem-causing microbiomes are blunt. Antibiotics wipe out whole populations of beneficial and harmful bacteria, probiotics have limited impact, and fecal transplants have shown some promise in specific areas, but face concerns with safety and acceptance.

The IGI team is developing a revolutionary new approach to precisely control microbiomes by building on two state-of-the-art methods pioneered by Doudna and Banfield that have both developed significantly over the past decade: CRISPR genome editing and genome-resolved metagenomics. Less than 1 percent of microbial species can be cultured in the lab, but genome-resolved metagenomics removes the need to grow individual species one-by-one by providing a detailed map of all organisms in a microbiome and the functions of their genes. Banfield and collaborators used these techniques in a 2016 paper in Nature Microbiology to develop a new, clearer picture of the tree of life, showing just how much of the tree is dominated by unseen microbes.

Pairing genome-resolved metagenomics with CRISPR genome editing provides the opportunity and the necessary knowledge to fine-tune microbiomes by making highly targeted changes to specific genes in specific microbes.

In a 2022 paper in Nature Microbiology, Doudna, Banfield, and their teams showed for the first time that they could precisely edit genes directly within complex microbiomes, including model systems that replicated natural soil and infant gut microbiomes. The new initiative builds on that work, and is focused on refining the toolkit into a precision microbiome editing platform, as well as creating a new class of interventions to treat and prevent human diseases, and reduce greenhouse gas emissions to help reach global climate goals.

Asthma affects 300 million children globally. We can treat asthma symptoms, but currently we have no treatments that can prevent or cure it. We do, however, know a promising new target thanks to research from Sue Lynch, co-PI on asthma applications for the new initiative and Director of the Benioff Center for Microbiome Medicine at UCSF.

Lynch and her collaborators found that different microbiome compositions in infant guts increase the risk of developing asthma. Follow-up research identified a specific inflammatory compound produced by gut bacteria in children who develop asthma and also pinpointed which bacteria produce the greatest concentration of that metabolite, promising targets for an intervention.

In the US, developing this therapy would have the greatest impact on people of color, who disproportionately shoulder the burden of asthma. Globally, it would have an outsized impact on people in low- and middle-income countries, where the majority of asthma-related deaths occur.

This is not the first time the IGI has taken on a project that involves translating a lab discovery into a real-world tool. A CRISPR-based therapy for sickle cell disease developed at the IGI is currently in a phase I clinical trial. Agricultural products, including a drought-tolerant variety of rice, are undergoing field trials.

To maximize the impact around the world, the IGI team has pledged to disseminate their learnings and tools to the wider research community, and work with global nonprofits to help scale this transformative approach.

3a8082e126